Difference between revisions of "Part:BBa K5083000:Design"

 
(→‎Design Notes)
 
(One intermediate revision by the same user not shown)
Line 7: Line 7:
  
 
===Design Notes===
 
===Design Notes===
−
a
 
−
 
−
 
  
 
===Source===
 
===Source===
  
−
a
+
NCBI_ID:2641
  
 
===References===
 
===References===
 +
[1] Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis[J]. Journal of Biological Chemistry, 2003, 278(1): 471-478.
 +
[2] Kim K S, Park J S, Hwang E, et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans[J]. Science, 2024, 385(6707): 438-446.
 +
[3] Kobayati A, Haidar A, Tsoukas M A. Glucagon‐like peptide‐1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?[J]. Diabetes, Obesity and Metabolism, 2022, 24(5): 769-787.

Latest revision as of 01:57, 14 September 2024


GLP-1


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

Source

NCBI_ID:2641

References

[1] Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis[J]. Journal of Biological Chemistry, 2003, 278(1): 471-478. [2] Kim K S, Park J S, Hwang E, et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans[J]. Science, 2024, 385(6707): 438-446. [3] Kobayati A, Haidar A, Tsoukas M A. Glucagon‐like peptide‐1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?[J]. Diabetes, Obesity and Metabolism, 2022, 24(5): 769-787.